Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.

摘要: Agomelatine, an MT1/MT2 receptor agonist and 5-HT2C antagonist antidepressant, is known to have beneficial effects on subjective sleep in major depressive disorder patients. This international multicenter, randomized, double-blind study compared the of agomelatine (25-50 mg/day) escitalopram (10-20 polysomnographic parameters patients treated up 24 weeks. A total 138 outpatients were randomly allocated (n=71) or (n=67). Treatment with was associated a reduction latency from week 2 onward. The difference between treatments significant all evaluations. Rapid eye movement increased agomelatine, between-group differences at every visit. Agomelatine preserved number cycles, whereas it decreased Assessments visual analogue scales indicated that treatment improved morning condition, reduced daytime sleepiness escitalopram.17-item Hamilton depression rating scale score both groups, statistically noninferior 6 Both well tolerated. showed clinical wake are different escitalopram.